- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Emergency department
- Respiratory syncytial virus
Population: General population
Individuals who do not belong to a defined subgroup with specific characteristics, representing the broader population
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- General population
- Infants (<1 year)
- Hospital
- Respiratory syncytial virus
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Intensive care unit
- Respiratory syncytial virus
- Blood sample
- General population
- Infants (<1 year)
- Outpatient clinic
- Respiratory syncytial virus
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Respiratory syncytial virus
- Blood sample
- Nasopharyngeal swab
- Nasal lining fluid sample
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Primary care
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Human metapneumovirus
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Infants (<1 year)
- Children (1-11 years)
- Adolescents (12-17 years)
- Hospital
- Non-hospital health centre
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Adenovirus
- Rhinovirus
- Parainfluenza Virus
- Metapneumovirus
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Primary care
- Respiratory syncytial virus
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab